Literature DB >> 15385635

Prognosis, treatment and outcome of childhood mesangiocapillary (membranoproliferative) glomerulonephritis.

Janette C Cansick1, Rachel Lennon, Carole L Cummins, Alexander J Howie, Mary E McGraw, Moin A Saleem, E Jane Tizard, Sally-Anne Hulton, David V Milford, C Mark Taylor.   

Abstract

BACKGROUND: Prognostic factors and outcome are incompletely known in childhood mesangiocapillary glomerulonephritis (MCGN). This study aimed to correlate renal outcome with clinical and histopathological variables.
METHODS: We conducted a two-centre retrospective analysis of children with MCGN.
RESULTS: Fifty-three children presented at a mean age of 8.8 years (range: 13 months-15 years). They were followed for a median of 3.5 years (range: 0-17 years). Histological classification identified 31 type 1, 14 type 2, two type 3 and six undetermined type. Mean renal survival [time to end-stage renal failure (ESRF)] was projected to be 12.2 years [confidence interval (CI): 9.7-14.6 years]. Five and 10 year renal survival was 92% (CI: 88-100%) and 83% (CI: 74-92%), respectively. Those with nephrotic syndrome at presentation had mean renal survival of 8.9 years (CI: 7.1-10.7 years) vs 13.6 years for those without (CI: 10.8-16.5 years) (P = 0.047). The mean estimated glomerular filtration rate (eGFR) at 1 year in those who progressed to ESRF was 52 vs 98 ml/min/1.73 m2 in those who did not (P < 0.001). Chronic damage scored on the first biopsy in 31 children (one centre) was positively associated with adverse renal outcome at 5 years: <20% was associated with 100% and > or =20% with 71% 5-year renal survival (P = 0.006). In 29 children treated with steroid there was a higher proportion (76%) with reduced eGFR at presentation and a significantly higher incidence of nephrotic syndrome (P = 0.002) and hypertension (P = 0.037). There were no significant differences in outcome eGFR, hypertension or proteinuria.
CONCLUSIONS: Nephrotic syndrome at presentation and subnormal eGFR at 1 year were adverse features. The finding that structural disease at onset predicted poor renal outcome at 5 years has implications for the design of therapeutic trials. Treatment of MCGN was variable and not evidence-based.

Entities:  

Mesh:

Year:  2004        PMID: 15385635     DOI: 10.1093/ndt/gfh484

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  14 in total

1.  Recurrence of membranoproliferative glomerulonephritis after renal transplantation in Denys-Drash.

Authors:  Thomas J Neuhaus; Walter Arnold; Ariana Gaspert; Helmut Hopfer; Andreas Fischer
Journal:  Pediatr Nephrol       Date:  2010-10-28       Impact factor: 3.714

2.  Clinical features and outcomes of 98 children and adults with dense deposit disease.

Authors:  Der-Fa Lu; Mikyung Moon; Lynne D Lanning; Ann Marie McCarthy; Richard J H Smith
Journal:  Pediatr Nephrol       Date:  2011-11-22       Impact factor: 3.714

3.  Positive C1q staining associated with poor renal outcome in membranoproliferative glomerulonephritis.

Authors:  Takashi Takei; Mitsuyo Itabashi; Takahito Moriyama; Ari Shimizu; Yuki Tsuruta; Ayami Ochi; Kayu Nakayama; Chihiro Iwasaki; Keiko Uchida; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2012-07-21       Impact factor: 2.801

4.  Streptococcal infection as possible trigger for dense deposit disease (C3 glomerulopathy).

Authors:  Julianne Prasto; Bernard S Kaplan; Pierre Russo; Elaine Chan; Richard J Smith; Kevin E C Meyers
Journal:  Eur J Pediatr       Date:  2014-01-03       Impact factor: 3.183

Review 5.  Making sense of the spectrum of glomerular disease associated with complement dysregulation.

Authors:  Sally Ann Johnson; Edwin K S Wong; C Mark Taylor
Journal:  Pediatr Nephrol       Date:  2013-07-14       Impact factor: 3.714

6.  C3 Glomerulopathy and Related Disorders in Children: Etiology-Phenotype Correlation and Outcomes.

Authors:  Edwin K S Wong; Kevin J Marchbank; Hannah Lomax-Browne; Isabel Y Pappworth; Harriet Denton; Katie Cooke; Sophie Ward; Amy-Claire McLoughlin; Grant Richardson; Valerie Wilson; Claire L Harris; B Paul Morgan; Svetlana Hakobyan; Paul McAlinden; Daniel P Gale; Heather Maxwell; Martin Christian; Roger Malcomson; Timothy H J Goodship; Stephen D Marks; Matthew C Pickering; David Kavanagh; H Terence Cook; Sally A Johnson
Journal:  Clin J Am Soc Nephrol       Date:  2021-09-22       Impact factor: 8.237

7.  Prognostic factors in children with membranoproliferative glomerulonephritis type I.

Authors:  Silvestre García-de la Puente; Iraida Luz Orozco-Loza; Samuel Zaltzman-Girshevich; Beatriz de Leon Bojorge
Journal:  Pediatr Nephrol       Date:  2008-06       Impact factor: 3.714

8.  Remission of membranoproliferative glomerulonephritis type I with the use of tacrolimus.

Authors:  Maha Haddad; Keith Lau; Lavjay Butani
Journal:  Pediatr Nephrol       Date:  2007-07-03       Impact factor: 3.714

Review 9.  Membranoproliferative glomerulonephritis.

Authors:  Bassam Alchi; David Jayne
Journal:  Pediatr Nephrol       Date:  2009-11-12       Impact factor: 3.714

Review 10.  Dense deposit disease and C3 glomerulopathy.

Authors:  Thomas D Barbour; Matthew C Pickering; H Terence Cook
Journal:  Semin Nephrol       Date:  2013-11       Impact factor: 5.299

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.